By Margarita Snegireva. The U.S. Food and Drug Administration approved entravirine as a medicine for those HIV-positive people who have failed treatment with other antiretrovirals.
Sold under the trade name Intelence, entravirine is a non-nucleoside reverse transcriptase inhibitor, which helps block an enzyme that the AIDS-causing virus needs to multiply, the FDA said in a statement. This is aimed at reducing the amount of HIV in the blood and boosting infection-fighting white blood cells.
Etravirine (formerly known as TMC-125, brand name Intelence) is a drug approved in the United States for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to entravirine. Etravirine is marketed by Tibotec, a subsidiary of Johnson & Johnson. In January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the first anti-HIV drug approved in 2008.
Tibotec is also working to introduce etravirine in other markets, particularly in the E.U. As of 2008, etravirine has not yet received EU regulatory approval.
Russian military repeatedly thwarted Turkey's attempts to deploy its troops to Syria, and stopped militants from moving further south